The present disclosure relates to co-crystals comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits.La présente invention concerne des co-cristaux comprenant N-[2,4-bis (1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoléine -3-carboxamide (composé 1) et un co-gabarit, et des procédés pour leur préparation. La présente invention concerne en outre des compositions pharmaceutiques comprenant les formes co-cristallines, ainsi que des méthodes de traitement au moyen de ceux-ci et des kits.
